Kancera AB Company Description

Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally.

The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer.

It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy.

Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.

Kancera AB (publ)

Country	Sweden
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Peter Selin

Contact Details

Address: Karolinska Institutet Science Park Solna, 171 65 Sweden
Phone	46 8 50 12 60 80
Website	kancera.com

Stock Details

Ticker Symbol	KAN
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0015658570
SIC Code	2836

Key Executives

Name	Position
Peter Selin	Chief Executive Officer
Dr. Thomas Olin Ph.D.	Executive Vice President and Director
Hans Richter	Chief Financial Officer
Dr. Robert Edfors	Chief Medical Officer